Sentinel Node Biopsy in Endometrial Cancer

Inclusion Criteria: 1. Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour); 2. Clinically stage I disease (disease confined to body of uterus); 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 4. Signed written informed consent; 5. Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning) 6. All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease 7. Myometrial Invasion on MRI of not more than 50%. (Only if participant is \<45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries). 8. Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women \< 2 years after the onset of menopause. Exclusion Criteria: 1. Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging. 2. Enlarged retroperitoneal pelvic and/or aortic lymph nodes (\>1 cm) on medical imaging; 3. Estimated life expectancy of less than 6 months; 4. Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy; 5. Patients who have previously received radiation treatment to the pelvis 6. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator); 7. Patient compliance and geographic proximity that do not allow adequate follow-up; 8. Patients with allergy to Indocyanine Green (ICG) 9. Patients who have had previous retroperitoneal surgery 10. Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy) 11. Other prior malignancies \<5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu 12. Uterine perforation during endometrial tissue sampling